Detection of phospho-STAT5 in mast cells: A reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation

British Journal of Haematology

Volumn 139, Issue 1, 2007, Pages 31-40

  Zuluaga Toro, Tania ^a   Hsieh, Fred H ^a   Bodo, Juraj ^a   Dong, Henry Y ^b   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Genzyme Genetics   (United States)

Author keywords

Kit; Mastocytosis; STAT5; Systemic mast cell disease

Indexed keywords

BIOLOGICAL MARKER; CD2 ANTIGEN; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; TRYPTASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL NUCLEUS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; INFORMATION PROCESSING; MALE; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PUVA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD2; BASE SEQUENCE; BIOLOGICAL MARKERS; BONE MARROW EXAMINATION; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MAST CELLS; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN-TYROSINE KINASES; SEQUENCE ALIGNMENT; STAT5 TRANSCRIPTION FACTOR; STEM CELL FACTOR; TRYPTASES;

EID: 34548559124     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06708.x     Document Type: Article

References (29)

1. Aboudola, S., Murugesan, G., Szpurka, H., Ramsingh, G., Zhao, X., Prescott, N., Tubbs, R.R., Maciejewski, J.P. Hsi, E.D. (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. American Journal of Surgical Pathology, 31, 233 239.
2. Akin, C., Kirshenbaum, A.S., Semere, T., Worobec, A.S., Scott, L.M. Metcalfe, D.D. (2000) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Experimental Hematology, 28, 140 147.
3. Baker, A.F., Dragovich, T., Ihle, N.T., Williams, R., Fenoglio-Preiser, C. Powis, G. (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clinical Cancer Research, 11, 4338 4340.
4. Barnstein, B.O., Li, G., Wang, Z., Kennedy, S., Chalfant, C., Nakajima, H., Bunting, K.D. Ryan, J.J. (2006) Stat5 expression is required for IgE-mediated mast cell function. Journal of Immunology, 177, 3421 3426.
5. Brizzi, M.F., Dentelli, P., Rosso, A., Yarden, Y. Pegoraro, L. (1999) STAT protein recruitment and activation in c-Kit deletion mutants. Journal of Biological Chemistry, 274, 16965 16972.
6. Buttner, C., Henz, B.M., Welker, P., Sepp, N.T. Grabbe, J. (1998) Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. Journal of Investigative Dermatology, 111, 1227 1231.
7. Deberry, C., Mou, S. Linnekin, D. (1997) Stat1 associates with c-kit and is activated in response to stem cell factor. Biochemical Journal, 327, 73 80.
8. Escribano, L., Diaz-Agustin, B., Nunez, R., Prados, A., Rodriguez, R. Orfao, A. (2002) Abnormal expression of CD antigens in mastocytosis. International Archives of Allergy and Immunology, 127, 127 132.
9. Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L.M., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 2366 2372.
10. Gotlib, J. (2006) KIT mutations in mastocytosis and their potential as therapeutic targets. Immunology and Allergy Clinics of North America, 26, 575 592.
11. Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D. Gilliland, D.G. (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood, 106, 721 724.
12. Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J. (eds) (2001) Tumours of Haematopoeitic and Lymphoid Tissues. IARC Press, Lyon.
13. Krokowski, M., Sotlar, K., Krauth, M.T., Fodinger, M., Valent, P. Horny, H.P. (2005) Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. American Journal of Clinical Pathology, 124, 560 568.
14. Linnekin, D. (1999) Early signaling pathways activated by c-Kit in hematopoietic cells. International Journal of Biochemistry and Cell Biology, 31, 1053 1074.
15. Longley, B.J., Tyrrell, L., Lu, S.Z., Ma, Y.S., Langley, K., Ding, T.G., Duffy, T., Jacobs, P., Tang, L.H. Modlin, I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics, 12, 312 314.
16. Longley, Jr., B.J., Metcalfe, D.D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.Z., Heitjan, D. Ma, Y. (1999) Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the United States of America, 96, 1609 1614.
17. Ogata, N., Kikuchi, Y., Kouro, T., Tomonaga, M. Takatsu, K. (1997) The activation of the JAK2/STAT5 pathway is commonly involved in signaling through the human IL-5 receptor. International Archives of Allergy and Immunology, 114 (Suppl. 1 24 27.
18. Ogata, N., Kouro, T., Yamada, A., Koike, M., Hanai, N., Ishikawa, T. Takatsu, K. (1998) JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation. Blood, 91, 2264 2271.
19. Pardanani, A. (2005) Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematologica, 114, 41 51.
20. Pardanani, A., Ketterling, R.P., Brockman, S.R., Flynn, H.C., Paternoster, S.F., Shearer, B.M., Reeder, T.L., Li, C.Y., Cross, N.C., Cools, J., Gilliland, D.G., Dewald, G.W. Tefferi, A. (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 102, 3093 3096.
21. Reber, L., Da Silva, C.A. Frossard, N. (2006) Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. European Journal of Pharmacology, 533, 327 340.
22. Shelburne, C.P., McCoy, M.E., Piekorz, R., Sexl, V., Roh, K.H., Jacobs-Helber, S.M., Gillespie, S.R., Bailey, D.P., Mirmonsef, P., Mann, M.N., Kashyap, M., Wright, H.V., Chong, H.J., Bouton, L.A., Barnstein, B., Ramirez, C.D., Bunting, K.D., Sawyer, S., Lantz, C.S. Ryan, J.J. (2003) Stat5 expression is critical for mast cell development and survival. Blood, 102, 1290 1297.
23. Sotlar, K., Escribano, L., Landt, O., Mohrle, S., Herrero, S., Torrelo, A., Lass, U., Horny, H.P. Bultmann, B. (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. American Journal of Pathology, 162, 737 746.
24. Sotlar, K., Horny, H.P., Simonitsch, I., Krokowski, M., Aichberger, K.J., Mayerhofer, M., Printz, D., Fritsch, G. Valent, P. (2004) CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. American Journal of Surgical Pathology, 28, 1319 1325.
25. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. Maciejewski, J.P. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173 2181.
26. Valent, P., Horny, H.P., Escribano, L., Longley, B.J., Li, C.Y., Schwartz, L.B., Marone, G., Nunez, R., Akin, C., Sotlar, K., Sperr, W.R., Wolff, K., Brunning, R.D., Parwaresch, R.M., Austen, K.F., Lennert, K., Metcalfe, D.D., Vardiman, J.W. Bennett, J.M. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 25, 603 625.
27. Valent, P., Akin, C., Sperr, W.R., Mayerhofer, M., Fodinger, M., Fritsche-Polanz, R., Sotlar, K., Escribano, L., Arock, M., Horny, H.P. Metcalfe, D.D. (2005) Mastocytosis: pathology, genetics, and current options for therapy. Leukemia and Lymphoma, 46, 35 48.
28. Wang, T., Alam, R., Langley, K.E. Klimpel, G.R. (2000) Stem cell factor and IL-2 act synergistically in inducing intraepithelial lymphocyte proliferation and cytokine production: upregulation of the IL-2 receptor gamma-chain and signaling via JAK-3. Cellular Immunology, 205, 62 71.
29. Worobec, A.S., Semere, T., Nagata, H. Metcalfe, D.D. (1998) Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer, 83, 2120 2129.